Sophiris Bio Inc. (NASDAQ:SPHS) – Equities researchers at Zacks Investment Research lowered their FY2016 earnings per share estimates for shares of Sophiris Bio in a research report issued on Tuesday. Zacks Investment Research analyst D. Bautz now forecasts that the firm will post earnings of ($0.56) per share for the year, down from their prior estimate of ($0.47). Zacks Investment Research also issued estimates for Sophiris Bio’s FY2017 earnings at ($0.33) EPS and FY2018 earnings at ($0.41) EPS.

SPHS has been the topic of several other reports. Roth Capital restated a “buy” rating and set a $8.00 price target on shares of Sophiris Bio in a report on Friday, November 11th. Piper Jaffray Cos. assumed coverage on shares of Sophiris Bio in a report on Tuesday, August 30th. They set an “overweight” rating and a $7.00 price target on the stock. Finally, Maxim Group boosted their price target on shares of Sophiris Bio from $4.00 to $6.00 and gave the company a “buy” rating in a report on Wednesday, August 10th.

Sophiris Bio (NASDAQ:SPHS) opened at 2.82 on Friday. The stock’s market capitalization is $63.78 million. The firm has a 50-day moving average price of $2.84 and a 200 day moving average price of $2.82. Sophiris Bio has a 52-week low of $0.80 and a 52-week high of $8.55.

Large investors have recently added to or reduced their stakes in the stock. KCG Holdings Inc. raised its stake in Sophiris Bio by 152.3% in the third quarter. KCG Holdings Inc. now owns 42,920 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 25,907 shares during the last quarter. Airain ltd raised its stake in Sophiris Bio by 99.1% in the third quarter. Airain ltd now owns 63,730 shares of the biopharmaceutical company’s stock valued at $198,000 after buying an additional 31,713 shares during the last quarter. JPMorgan Chase & Co. acquired a new stake in Sophiris Bio during the third quarter valued at about $139,000. Citadel Advisors LLC raised its stake in Sophiris Bio by 65.2% in the second quarter. Citadel Advisors LLC now owns 49,176 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 19,402 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in Sophiris Bio by 90.3% in the second quarter. Vanguard Group Inc. now owns 331,000 shares of the biopharmaceutical company’s stock valued at $712,000 after buying an additional 157,100 shares during the last quarter. 5.61% of the stock is owned by institutional investors and hedge funds.

Sophiris Bio Company Profile

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

5 Day Chart for NASDAQ:SPHS

Receive News & Stock Ratings for Sophiris Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio Inc. and related stocks with our FREE daily email newsletter.